Related Experiment Video
Updated: Mar 11, 2026
A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate NMDA Receptor in Blood
Published on: January 9, 2018
Anti- N-Methyl-d-Aspartate (NMDA) Receptor Encephalitis
Ilana Kahn1, Guy Helman1,2, Adeline Vanderver1,2
11 Department of Neurology, Children's National Health System, NW, Washington, DC, USA.
Pediatric neurologists commonly use intravenous immunoglobulin and methylprednisone for anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, often initiating rituximab. Gaps remain in NMDAR encephalitis treatment timing and duration.
Area of Science:
- Neuroimmunology
- Pediatric Neurology
Background:
- Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a treatable autoimmune neurological disorder.
- Current immunotherapy approaches lack standardization in pediatric cases.
Purpose of the Study:
- To survey child neurologists regarding current practices for treating anti-NMDAR encephalitis.
- To identify areas of consensus and knowledge gaps in pediatric immunotherapy.
Main Methods:
- An anonymous online survey was distributed to members of the Child Neurology Society.
- 151 pediatric neurologists completed the survey, detailing their treatment strategies.
Main Results:
- Uniformity exists in first-line treatments: intravenous immunoglobulin and methylprednisone.
- Rituximab is frequently used as a first disease-modifying therapy.
- Uncertainty persists regarding the optimal timing for adding disease-modifying therapy and its duration.
Conclusions:
- Established treatment agreements can form the basis for standardized pediatric anti-NMDAR encephalitis guidelines.
- Further research and evidence-based clinical trials are needed to address knowledge gaps in treatment protocols.
More Related Videos
10:19High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
Published on: November 23, 2013
08:20Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis
Published on: June 2, 2022
